October 19, 2021 – Johnson & Johnson’s sales climbed in the latest quarter compared with the same stretch of last year, reflecting a return of more doctor’s visits and medical procedures after the pandemic disrupted the industry.
Here are five relevant highlights from the report.
- Medical-device sales grew 7.6% amid a higher level of surgical procedures
- The company’s revenue rose 11% year over year in the third quarter to $23.34 billion
- Pharmaceutical sales were up 14%, as a result of more prescriptions of drugs for multiple myeloma, inflammatory diseases and other conditions
- Johnson & Johnson’s sales of consumer products such as Tylenol, Motrin and skin-care lines rose 5.7%
- The quarterly report will be the last released during the tenure of CEO Alex Gorsky, who took up the position nine years ago. Joaquin Duato, a longtime executive at the company, will assume the role of CEO in January.